Skip to content
10-Q

Quarterly Report

SPRINGWORKS THERAPEUTICS, INC.

0001773427-25-000015

← back to feed
Filed
May 9, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 75.32M sh
Shares Diluted Q1 2025 · Mar 31, 2025 74.89M sh
Shares Diluted Q1 2025 · Mar 31, 2024 73.77M sh
Stock Repurchased Q1 2025 · Mar 31, 2025 $12.87M
Stock Repurchased Q1 2025 · Mar 31, 2024 $6.5M
Capex Q1 2025 · Mar 31, 2025 $30K
Capex Q1 2025 · Mar 31, 2024 $577K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$68.76M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$78.93M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $63.77M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $69.75M
Stockholders Equity Q1 2025 · Mar 31, 2025 $417.4M
Stockholders Equity Q1 2025 · Dec 31, 2024 $481.1M
Stockholders Equity Q1 2025 · Mar 31, 2024 $567.44M
Stockholders Equity Q1 2025 · Dec 31, 2023 $626.22M
Current Liabilities Q1 2025 · Mar 31, 2025 $82.27M
Current Liabilities Q1 2025 · Dec 31, 2024 $99.99M
Total Liabilities Q1 2025 · Mar 31, 2025 $87.96M
Total Liabilities Q1 2025 · Dec 31, 2024 $106.17M
Current Assets Q1 2025 · Mar 31, 2025 $356.32M
Current Assets Q1 2025 · Dec 31, 2024 $380.47M
Total Assets Q1 2025 · Mar 31, 2025 $505.36M
Total Assets Q1 2025 · Dec 31, 2024 $587.28M
Eps Diluted Q1 2025 · Mar 31, 2025 −$1.11
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.18
Eps Basic Q1 2025 · Mar 31, 2025 −$1.11
Eps Basic Q1 2025 · Mar 31, 2024 −$1.18
Sga Expense Q1 2025 · Mar 31, 2025 $76.5M
Sga Expense Q1 2025 · Mar 31, 2024 $60.11M
Rd Expense Q1 2025 · Mar 31, 2025 $49.6M
Rd Expense Q1 2025 · Mar 31, 2024 $53.62M
Net Income Q1 2025 · Mar 31, 2025 −$83.19M
Net Income Q1 2025 · Mar 31, 2024 −$87.39M
Operating Income Q1 2025 · Mar 31, 2025 −$80.54M
Operating Income Q1 2025 · Mar 31, 2024 −$93.93M
Cost Of Revenue Q1 2025 · Mar 31, 2025 $3.53M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $1.2M